Aradigm
HomeAboutProductsTechnologiesInvestorsCareers
Press Releases

Press Releases

All Releases
Aradigm Provides Further Comments on Restructuring and Cash Used in Operations
May 17, 2006
Aradigm Provides Further Comments on Restructuring and Cash Used in Operations HAYWARD, CA, May 17, 2006 (MARKET WIRE via COMTEX News Network) -- Aradigm Corporation (NASDAQ: ARDM) today is providing further comments on points made in the company's recent financial press release and corresponding
Aradigm Reports First Quarter 2006 Financial Results and Corporate Restructuring
May 15, 2006
Aradigm Reports First Quarter 2006 Financial Results and Corporate Restructuring HAYWARD, CA, May 15, 2006 (MARKET WIRE via COMTEX News Network) -- Aradigm Corporation (NASDAQ: ARDM) today announced financial results for the first quarter of 2006 ended March 31, 2006 and a corporate restructuring.
Aradigm Receives FDA Orphan Drug Designation of Liposomal Ciprofloxacin for Cystic Fibrosis
May 09, 2006
Aradigm Receives FDA Orphan Drug Designation of Liposomal Ciprofloxacin for Cystic Fibrosis HAYWARD, CA, May 09, 2006 (MARKET WIRE via COMTEX News Network) -- Aradigm Corporation (NASDAQ: ARDM) today announced it has received orphan drug designation from the U.S.
Aradigm Announces Approval of Application to Transfer Stock Listing to Nasdaq Capital Markets
May 01, 2006
Aradigm Announces Approval of Application to Transfer Stock Listing to Nasdaq Capital Markets HAYWARD, CA, May 01, 2006 (MARKET WIRE via COMTEX News Network) -- Aradigm Corporation (NASDAQ: ARDM) today announced that The Nasdaq Stock Market has approved its application to transfer the listing of
Aradigm Announces Update by Novo Nordisk on AERx Inhaled Insulin Phase 3 Clinical Program
Apr 28, 2006
Aradigm Announces Update by Novo Nordisk on AERx Inhaled Insulin Phase 3 Clinical Program HAYWARD, CA, Apr 28, 2006 (MARKET WIRE via COMTEX News Network) -- Aradigm Corporation (NASDAQ: ARDM) today reported that its partner, Novo Nordisk, has provided additional details concerning the resumption of
Aradigm and Canadian Department of National Defence Extend AERx Liposomal Ciprofloxacin Development Program
Apr 26, 2006
Aradigm and Canadian Department of National Defence Extend AERx Liposomal Ciprofloxacin Development Program HAYWARD, CA, Apr 26, 2006 (MARKET WIRE via COMTEX News Network) -- Aradigm Corporation (NASDAQ: ARDM) today announced that Defence R&D Canada (DRDC) has extended the development program for
Aradigm Corporation First Quarter 2006 Earnings and Conference Call Notification
Apr 26, 2006
Aradigm Corporation First Quarter 2006 Earnings and Conference Call Notification HAYWARD, CA, Apr 26, 2006 (MARKET WIRE via COMTEX News Network) -- In the news release, "Aradigm Corporation First Quarter 2006 Earnings and Conference Call Notification," issued Monday, 04/24/2006, by Aradigm
Aradigm Corporation Applies to Transfer Listing to Nasdaq Capital Market
Apr 24, 2006
Aradigm Corporation Applies to Transfer Listing to Nasdaq Capital Market HAYWARD, CA, Apr 24, 2006 (MARKET WIRE via COMTEX News Network) -- Aradigm Corporation (NASDAQ: ARDM) announced today its intent to move trading of its common stock from the Nasdaq National Market to the Nasdaq Capital Market,
Aradigm Corporation Receives Nasdaq Notice of Non-Compliance With Nasdaq Marketplace Rules
Mar 31, 2006
Aradigm Corporation Receives Nasdaq Notice of Non-Compliance With Nasdaq Marketplace Rules HAYWARD, CA, Mar 31, 2006 (MARKET WIRE via COMTEX News Network) -- Aradigm Corporation (NASDAQ: ARDM) announced that it received a notice today from Nasdaq indicating that the Company has not met the
Aradigm and APT Pharmaceuticals Initiate Phase 2 Clinical Program of Novel Treatment for Asthma
Mar 23, 2006
Aradigm and APT Pharmaceuticals Initiate Phase 2 Clinical Program of Novel Treatment for Asthma HAYWARD, CA and TUCSON, AZ, Mar 23, 2006 (MARKET WIRE via COMTEX News Network) -- Aradigm Corporation (NASDAQ: ARDM) and APT Pharmaceuticals Inc., a privately held biotechnology company, today announced
Aradigm Reports Novo Nordisk to Initiate Additional Phase 3 Clinical Trials of AERx Diabetes Management System
Mar 07, 2006
Growing Body of Positive Clinical Data Support These Additional Trials
Aradigm Corporation to Present at the Cowen & Co. 26th Annual Health Care Conference
Feb 28, 2006
Aradigm Corporation to Present at the Cowen & Co. 26th Annual Health Care Conference HAYWARD, CA, Feb 28, 2006 (MARKET WIRE via COMTEX News Network) -- Aradigm Corporation (NASDAQ: ARDM) announced today that Dr. Bryan Lawlis, Aradigm's President and Chief Executive Officer, will present at the
Aradigm Announces Fourth Quarter and Year End 2005 Financial Results
Feb 22, 2006
Aradigm Announces Fourth Quarter and Year End 2005 Financial Results HAYWARD, CA -- 02/22/2006 -- Aradigm Corporation (NASDAQ: ARDM) today announced financial results for the fourth quarter and year ended December 31, 2005. The company reported contract revenues for the three months ended December
Aradigm Corporation Fourth Quarter and Full Year 2005 Earnings and Conference Call Notification
Feb 15, 2006
Aradigm Corporation Fourth Quarter and Full Year 2005 Earnings and Conference Call Notification HAYWARD, CA, Feb 15, 2006 (MARKET WIRE via COMTEX News Network) -- Aradigm Corporation (NASDAQ: ARDM) will announce its fourth quarter and full year 2005 financial results on Wednesday February 22, 2006,
Aradigm Files Request for Orphan Drug Designation for Inhaled Liposomal Ciprofloxacin for Cystic Fibrosis
Jan 06, 2006
Aradigm Files Request for Orphan Drug Designation for Inhaled Liposomal Ciprofloxacin for Cystic Fibrosis HAYWARD, CA--(MARKET WIRE)--Jan 5, 2006 -- Aradigm Corporation (NasdaqNM: ARDMD - News ) today announced that it has filed a request for orphan drug designation with the United States Food and
Displaying 221 - 235 of 235
CONTACT NEWS & EVENTS LEGAL SITE MAP ©2018 Aradigm Corporation. All Rights Reserved.